Skip to main content
Terug
Watch Compare

Barinthus Biotherapeutics plc.

Datakwaliteit: 100%
BRNS
NASDAQ Manufacturing Chemicals
€ 0,59
▼ € 0,01 (-1,33%)
6 months return
—
Momentum
Neutral
ROE
-71,11%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-71,11%
Onder sectorgemiddelde (-54,68%)
ROIC-51,79%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio8,04
Interest Coverage-1383,43

Waardering

PE (TTM|NTM)
-0,35 | -0,49
Boven sectorgemiddelde (-1,49)
P/B Ratio0,27
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -48,02 M

Price History

Financiële Trends

Koersdoel Analisten

2 analisten
Buy
+827.5%
upside to target
Huidig
€ 0,59
Consensus Target
€ 5,50
€ 4,00
Laag
€ 7,00
Hoog
Vooruitzicht
Forward K/W
-0,49
Forward WPA
-€ 1,15
Omzet Sch.
0,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,28 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 0,49 -€ 0,52 -€ 0,24 -€ 0,27 — —
Estimate -€ 0,36 -€ 0,33 -€ 0,40 -€ 0,35 -€ 0,28 -€ 0,28
Verrassing -36,11% -57,58% +38,23% +21,68% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -71,11% · Net Margin: N/A
Revenue (TTM) 0,0 Net Income (TTM) -66,43 M
ROE -71,11% ROA -55,64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -48,02 M
ROIC -51,79% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 8,04
Debt / Equity N/A Current Ratio 8,04
Interest Coverage -1383,43 Asset Turnover 0,00
Working Capital 75,98 M Tangible Book Value 69,56 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,35 · EV/EBITDA: N/A
P/E Ratio -0,35 Forward P/E -0,49
P/B Ratio 0,27 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -207,13%
Market Cap 23,18 M Enterprise Value -51,09 M

Per Share

EPS: -1,64 · FCF/Share: -1,17
EPS (Diluted TTM) -1,64 Revenue / Share 0,00
FCF / Share -1,17 OCF / Share -1,17
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 72,28% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 72,28%
SBC-Adj. FCF -48,93 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 14,97 M 802.000,0 44,70 M 268.000,0
Net Income -66,43 M -61,07 M -73,35 M 5,34 M -50,87 M
EPS (Diluted) -1,64 -1,55 -1,91 0,14 -1,96
Gross Profit — — — — —
Operating Income -70,56 M -67,97 M -83,91 M -4,04 M -45,22 M
EBITDA — — — — —
R&D Expenses 25,56 M 42,24 M 44,87 M 42,35 M 20,37 M
SG&A Expenses — — — — —
D&A 5,85 M 5,80 M 5,43 M 4,32 M 602.000,0
Interest Expense 51.000,0 53.000,0 28.000,0 19.000,0 2,67 M
Income Tax -175.000,0 -44.000,0 -3,08 M -4,47 M -28.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 98,17 M 160,33 M 214,51 M 270,21 M 280,72 M
Total Liabilities 23,88 M 30,19 M 27,51 M 27,00 M 28,15 M
Shareholders' Equity 74,21 M 130,03 M 186,78 M 242,90 M 252,56 M
Total Debt — — — — —
Cash & Equivalents 70,46 M 110,66 M 142,09 M 194,39 M 214,05 M
Current Assets 77,79 M 125,74 M 156,91 M 213,04 M 226,77 M
Current Liabilities 10,02 M 15,66 M 12,60 M 12,24 M 11,16 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,4 -1,5
P/B 0,3 1,6
ROE % -71,1 -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3